Suppl. Fig 7

A

Log–rank, P = 0.96

PIK3CA wild-type

PIK3CA mutant

Number at risk

Time (Months)

Overall survival (%)

B

Log–rank, P = 0.32

PTEN wild-type

PTEN mutant

Number at risk

Time (Months)

Overall survival (%)

C

Log–rank, P = 0.34

PI3K/AKT pathway wild-type

PI3K/AKT pathway mutant

Number at risk

Time (Months)

Overall survival (%)

D

Log–rank, P = 0.16

ERBB3 wild-type

ERBB3 mutant

Number at risk

Time (Months)

Overall survival (%)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

doi: 10.1136/jitc-2020-002223